Clinton (Clint) Musil serves as Chief Financial Officer and Chief Business Officer at CatalYm. He brings decades of experience in the biopharmaceutical industry, including significant expertise in strategic planning and financial management with a proven track record in completing successful financings, pharmaceutical partnerships, and strategic transactions. He joins CatalYm from Skyhawk Therapeutics, where he held several roles of increasing responsibility, culminating in his position as CEO. Clint has completed multiple IPOs and held several executive roles at public biotech company including at ARMO Biosciences, which was acquired by Eli Lilly for $1.6 billion. Earlier in his career, Clint served in business roles within pharma, as an investment banker and as an investor. He holds an MBA from Harvard Business School and BSc in Molecular and Cellular Biology from the University of Arizona.